Joined: Fri Feb 06, 2009 11:00 am Posts: 579 Location: England, UK
|
Hi Folks, I did a bit of digging and was able to establish that, for the UK and Ireland, Danish pharmaceutical group Lundbeck has acquired the rights for nalmefene. Looking at the Lundbeck website, I discovered the following: http://www.lundbeck.com/investor/releas ... 425_EN.aspIn the above article, it says: " Based on the earlier trials, Lundbeck is now launching three phase III trials enrolling more than 1,800 patients randomised into groups receiving nalmefene and placebo respectively. The first two trials, in which patients are treated over a period of six months, primarily aim to demonstrate the efficacy of nalmefene, whilst the objective of the last study, in which patients are treated for 12 months, is particularly to confirm that the compound is well-tolerated. The first data from the trials are expected in the first half of 2011". So, in the UK and Ireland, it looks as though nalmefene is at least two years away. Unfortunately, I wasn't able to find out about the worldwide availability of nalmefene. V.
_________________ Weekly Consumption Wk01-10: 86, 98, 103, 104, 97, 92, 102, 103, 102, 107 Wk11-20: 100, 99, 100, 105, 108, 108, 89, 95, 105, 97 Wk21-30: 97, N/R, N/R, 97, 105, N/R, N/R, 107, 97, 98 Wk31-40: 93, 88, 87, 87, 91, 92, 94, N/R UK units N/R = Not Recorded
|
|